Biotechnology

Adolore BioTherapeutics Invited to Present at the 16th Annual Pain Therapeutics Summit

November 14, 2022 10:00 AM

Company to discuss its next generation, disease-modifying, non-opioid analgesic gene therapy in development for the treatment of chronic pain DELRAY BEACH, FL / ACCESSWIRE / November 14, 2022 / Adolore BioTherapeutics, Inc. ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for chronic pain, today announced that Roy Clifford Levitt, MD, Founder and Executive...

Read more

EV Biologics Initiates PCAOB Audit to Seek Uplift to OTCQX

November 14, 2022 9:45 AM

TAMPA, FL / ACCESSWIRE / November 14, 2022 / EV Biologics Corp, (OTC PINK:YECO), today announced that it is initiating a PCAOB audit for 2021 and 2022 and intends to file an application to list on the OTCQX market during Q1, 2023. This PCAOB audit is a necessary step to finalize the previously filed corporate name change with FINRA, which will also update the trading symbol. The audit is also a requirement for the Company's application to...

Read more

Vaso Corporation Announces Financial Results for Third Quarter 2022

November 14, 2022 9:00 AM

Net income for the quarter reached $2.5 million on record revenue PLAINVIEW, NY / ACCESSWIRE / November 14, 2022 / Vaso Corporation ("Vaso") (OTCQB:VASO) today reported its operating results for the three months ended September 30, 2022. "For the third quarter of 2022, the Company recorded a net income of $2.5 million on revenue of $20.0 million, compared to the prior year's third quarter net income of $0.7 million on revenue of $18.4 million....

Read more

Midatech Pharma PLC - First Patient Enrolled in Phase 1 Study of MTX-110

November 14, 2022 2:00 AM

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 14, 2022 / Midatech Pharma PLC (AIM:MTPH.L; Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the enrolment of the first patient into its Phase 1 study of MTX110 in recurrent glioblastoma (rGB) (NCT 05324501)...

Read more

BioInvent and Transgene Joint Paper on BT-001 Wins JITC Best Oncolytic and Local Immunotherapy Paper Award for 2022

November 11, 2022 8:10 AM

Winning paper demonstrates potential of vectorized novel CTLA-4 targeting antibodies and was highlighted at SITC 2022 Reaffirms potential of BT-001, an oncolytic virus co-developed by Transgene and BioInvent currently in Phase 1/2a trial LUND, SWEDEN / ACCESSWIRE / November 11, 2022 / BioInvent International AB (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory...

Read more

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 10, 2022 5:20 PM

- DMT310 Phase 2 topline results in moderate-to-severe rosacea anticipated in December 2022 - - Initiation of DMT310 Phase 3 for moderate-to-severe acne expected in 1H 2023 - SAN DIEGO, CA / ACCESSWIRE / November 10, 2022 / Dermata Therapeutics, Inc. (Nasdaq:DRMA;DRMAW) ("Dermata," or the "Company"), a clinical-stage biopharmaceutical company focusing on the treatment of medical and aesthetic skin conditions, today highlighted recent corporate...

Read more

Lifeloc Reports Third Quarter 2022 Results

November 10, 2022 5:18 PM

WHEAT RIDGE, CO / ACCESSWIRE / November 10, 2022 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the third quarter ended September 30, 2022. Third Quarter Financial Highlights Lifeloc posted quarterly net revenue of $2.032 million in the third quarter of 2022, resulting in a quarterly net loss of $(87) thousand, or...

Read more

NovAccess Global Appoints Healthcare IP Consultant Dr. Peter Weinstein to Scientific Advisory Board

November 10, 2022 2:00 PM

CLEVELAND, OH / ACCESSWIRE / November 10, 2022 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the appointment of Peter Weinstein, PH.D., JD to its Scientific Advisory Board. Dr. Weinstein is a well-regarded intellectual property attorney and healthcare industry consultant who has been serving as legal counsel to NovAccess Global subsidiary StemVax Therapeutics...

Read more

Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia

November 10, 2022 9:20 AM

KELOWNA, BC / ACCESSWIRE / November 10, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DEM-A22-1 is expected to begin on November 15, 2022. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD") may potentially have therapeutic utility against dementia. Lexaria has...

Read more

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

November 10, 2022 7:05 AM

- Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development - Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward FRAMINGHAM, MA / ACCESSWIRE / November 10, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on...

Read more

Save the Date: BioInvent to Host R&D Day in Stockholm on December 8, 2022

November 10, 2022 4:50 AM

LUND, SWEDEN / ACCESSWIRE / November 10, 2022 / BioInvent International (STO:BINV) Lund, Sweden, November 10, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, will host an R&D Day in Stockholm on Thursday December 8, 2022 for investors, analysts and media. The R&D Day will feature...

Read more

Media Alert: BrainChip Talks To Arm About the Importance of Ecosystem Partnerships on Latest Podcast

November 9, 2022 5:30 PM

LAGUNA HILLS, CA / ACCESSWIRE / November 9, 2022 / BrainChip Holdings Ltd (ASX:BRN), (OTCQX:BRCHF), (ADR:BCHPY), the world's first commercial producer of ultra-low power neuromorphic AI IP, today announced that Kevin Ryan, Senior Director Go-to-Market and Ecosystem - IoT at Arm, shares his insight as part of the "This is our Mission" podcast. He joins BrainChip Vice President of Ecosystem and Partnerships Rob Telson to help listeners understand...

Read more

Pieris Pharmaceuticals to Present at Jefferies London Healthcare Conference

November 9, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 7:25 AM GMT. A webcast of the company's...

Read more

Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes

November 8, 2022 9:10 AM

KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program DIAB-A22-1 is expected to begin on schedule today. This is Lexaria's first-ever study to investigate whether its patented DehydraTECH-processed cannabidiol ("CBD") may potentially have therapeutic utility against diabetes. Lexaria has previously...

Read more

CEN Biotech Inc. Announces Word Presto Partner Program

November 8, 2022 8:30 AM

WINDSOR, ON / ACCESSWIRE / November 8, 2022 / CEN Biotech Inc. ("CEN" or the "Company") (OTCQB:CENBF), a global holding company focused on the development of leading-edge digital media technologies, LED lighting technology and hemp-based products, is pleased to announce the formal launch of its Word Presto Partner Program for resellers and affiliates. Word Presto is a product and a service that provides people with a customized web design...

Read more

EV Hotel Corp. and Plandai Biotechnologies Enter Into Asset Acquisition Agreement to Create the Leading Smart Hotel Brand - EV Hotel Corp.

November 8, 2022 12:00 AM

SAN DIEGO, CA / ACCESSWIRE / November 8, 2022 / (OTC PINK:PLPL) - Plandai Biotechnology, Inc. ("Plandai" or the "Company") today announces its entry into an asset acquisition agreement with EV Hotel Corp. EV Hotel™ developed the world's first proprietary, disruptive hospitality platform called the "smart hotel," which combines technology, automation, IoT, crypto, and NFT with best-in-class service, stylish design, and upscale amenities to...

Read more

Apollo Endosurgery to Participate in Upcoming Investor Conferences

November 7, 2022 9:00 AM

AUSTIN, TX / ACCESSWIRE / November 7, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that its senior management team will host investor meetings at four investor conference events during November and December 2022. Event: Stifel 2022 Healthcare Conference Date: Wednesday, November 16, 2022 Presentation: 2:25 p.m....

Read more

enVVeno Medical Successfully Passes Preliminary FDA Safety Review for the VenoValve U.S. Pivotal Study

November 7, 2022 8:45 AM

The Company submitted safety data for the first 20 patients enrolled in the ongoing SAVVE U.S. pivotal study for the VenoValve Following the initial safety data review by the FDA, the SAVVE study is cleared to continue without modification or interruption The Company currently has 33 patients enrolled in the study and expects to be fully enrolled by the end of Q2 of 2023 With $42.7 million of cash and investments reported at the end of Q3 of...

Read more

Announcement from Biovica International AB's Extra General Meeting

November 7, 2022 8:05 AM

UPPSALA, SE / ACCESSWIRE / November 7, 2022 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The extra general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 7 November 2022 in Stockholm and the following resolutions were passed by the meeting. RIGHTS ISSUE The extra general meeting resolved to approve the board of directors resolution from 18 October 2022 on a rights issue of a maximum of...

Read more

Black Bird Biotech Provides Shareholder Update Ahead of MJBizCon 2022 in Las Vegas

November 3, 2022 9:25 AM

FLOWER MOUND, TX / ACCESSWIRE / November 3, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer and distributor of plant-based MiteXstreamTM biopesticide, is pleased to provide the following shareholder update. BBBT's President, Fabian Deneault, stated, "At the August 2022 Cannabis Conference, MiteXstreamTM seemed to be the ‘belle of the ball.' We were pleased that so many attendees and other vendors expressed such positive comments about...

Read more